Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Next revisionBoth sides next revision
home:physicians:concerns [06.05.2019] – [Read also] sallieqhome:physicians:concerns [07.13.2019] – [Concerns about immunopathology] sallieq
Line 7: Line 7:
 ===== Concerns about lack of clinical evidence ===== ===== Concerns about lack of clinical evidence =====
  
-  - **"There are no well-controlled studies to support the use of the Marshall Protocol for a given indication."** This statement is accurate. As of 2012, patients and physicians who choose to use and administer the MP do so based on the following evidence:+  - **"There are no well-controlled studies to support the use of the Marshall Protocol for a given indication."** This statement is accurate. In 2012, patients and physicians who chose to use and administer the MP did so based on the following evidence:
     * a [[home:publications:proal_molecular_2011|2011 case series of MP patients]] appearing in the (Nature Publishing Group) journal //Clinical & molecular immunology//     * a [[home:publications:proal_molecular_2011|2011 case series of MP patients]] appearing in the (Nature Publishing Group) journal //Clinical & molecular immunology//
     * a [[home:publications:mp2008_survey|2008 retrospective survey]] of 100 MP patients with autoimmune diagnoses     * a [[home:publications:mp2008_survey|2008 retrospective survey]] of 100 MP patients with autoimmune diagnoses
Line 17: Line 17:
  
 For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment: For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment:
-  * evidence for the efficacy of MP versus other available treatment options(({{pubmed>long:19050187}})) +  * alternative hypotheses and evidence of research (({{pubmed>long:    15246025}})), (({{pubmed>long:16403216}})), (({{pubmed>long:23370376}})), (({{pubmed>long:18200565}}))  
-  * 2013 material on patient response, see section below +  * evidence for the efficacy of MP versus other available treatment in 2013 data on patient response, see section below 
   * patients' expressed preferences and values(({{pubmed>long:19050187}}))   * patients' expressed preferences and values(({{pubmed>long:19050187}}))
   * additional benefits of Olmesartan [[https://mpkb.org/home/protocol/olmesartan#other_benefits_of_olmesartan_in_patients_-_recent_studies|other researched benefits]]   * additional benefits of Olmesartan [[https://mpkb.org/home/protocol/olmesartan#other_benefits_of_olmesartan_in_patients_-_recent_studies|other researched benefits]]
Line 27: Line 27:
 <html></p></div></html> <html></p></div></html>
  
-===== Recorded success rates assessed 2013  =====+==== Recorded results assessed 2013  ====
  
 <blockquote>//DJ posted// :- During the summer of 2013 I looked at 2,000 records of people using the Marshall Protocol.</blockquote>  <blockquote>//DJ posted// :- During the summer of 2013 I looked at 2,000 records of people using the Marshall Protocol.</blockquote> 
Line 81: Line 81:
  
   - **"A temporary increase in symptoms or laboratory values means the treatment is not working."** – \\ Immunopathology is an increase in one's present symptoms of Th1 inflammation or a return of previous Th1 inflammatory symptoms, that is caused by cytokines and endotoxins being released from dying bacteria. In some cases there may be a temporary experience of symptoms attributable to a previously unexperienced condition. Immunopathology is a necessary part of recovery. The amount of immunopathology a patient experiences on the Marshall Protocol (MP) is correlated with disease severity. Patients who are less sick will have comparatively less strong immunopathology. [[home:protocol:immunopathology|Read more →]]   - **"A temporary increase in symptoms or laboratory values means the treatment is not working."** – \\ Immunopathology is an increase in one's present symptoms of Th1 inflammation or a return of previous Th1 inflammatory symptoms, that is caused by cytokines and endotoxins being released from dying bacteria. In some cases there may be a temporary experience of symptoms attributable to a previously unexperienced condition. Immunopathology is a necessary part of recovery. The amount of immunopathology a patient experiences on the Marshall Protocol (MP) is correlated with disease severity. Patients who are less sick will have comparatively less strong immunopathology. [[home:protocol:immunopathology|Read more →]]
 +
 +see also [[home:protocol:olmesartan:safety|https://mpkb.org/home/protocol/olmesartan/safety#recent_research|research into enteropathy]] 
  
 ===== Concerns about antibiotics=====  ===== Concerns about antibiotics===== 
home/physicians/concerns.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.